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ABBREVIATIONS AND SOME DEFINITIONS 
 
APA = American Psychiatric Association 
BPRS = Brief Psychiatric Rating Scale 
CLO = clozapine 
CNS = central nervous system 
D1-5 = dopamine receptors, types 1-5 
DSM-III = Diagnostic and Statistical Manual of Mental Disorders, Third 
Edition, APA 1980  
DSM-III-R = DSM, Third Edition, Revised, APA 1987 
EEG = electroencephalography 
FC = fronto-central scalp area 
FCleft  = left fronto-central scalp area (EEG electrodes Fp1, F3, C3) 
FCright = right fronto-central scalp area (EEG electrodes Fp2, F4, C4)  
FCz = midline fronto-central scalp area (EEG electrodes FpZ, FZ, CZ) 
FFT = Fast Fourier Transformation = an algorithm used in digital signal 
processing that break down complex signals into elementary components 
(www.pcmag.com/encyclopedia) 
GABA = gamma-aminobutyric acid = an inhibitory neurotransmitter 
IL = interleukin = family of proteins modulating immune response 
MENTAL DISORDER = concept comprises a broad range of problems, 
generally characterized by some combination of abnormal thoughts, emotions, 
behaviour and relationships with others (www.WHO.int) 
MENTAL ILLNESS = chronic mental malfunction, when people's capacities to 
respond to the world, to absorb and remember information, respond with 
appropriate emotions, and form coherent plans are impaired (www.answers.com 
/ Philosophy Dictionary) 
MO = peripheral blood monocytes 
MOn = peripheral blood monocytes, not stimulated  
MOs = peripheral blood monocytes, stimulated 
NO = nitric oxide = signalling molecule and reactive oxygen species 
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PANSS = Positive and Negative Syndrome Scale  
PANSSG = PANSS general psychopathology scale 
PANSSN = PANSS negative scale 
PANSSP = PANSS positive scale 
PMA = phorbol myristate acetate = a substance which in vitro triggers cellular 
immune reactions in immune cells  
QEEG = quantitative electroencephalography = quantitatively analysed digital 
EEG record 
ROS = reactive oxygen species = molecules or ions that contribute to the 
microbicidal activity of phagocytes, regulation of signal transduction and gene 
expression, and the oxidative damage to nucleic acids; proteins; and lipids 
(http://ghr.nlm.nih.gov/ghr/glossary) 




This work studies the effect of clozapine (CLO) on the electroencephalography 
(EEG) and reactive oxygen species (ROS) production by peripheral blood 
monocytes (MO) in patients with schizophrenia (SCH). The aim of the study 
was to investigate the mechanism of action of CLO, to clarify the effect of CLO 
on EEG absolute power spectrum and ROS production, and explore the 
relationship of these effects with clinical response. We also tried to clarify 
whether the EEG changes or ROS production would help to identify the patients 
who were most likely to respond to treatment with CLO.  
 
Our findings suggest that the amount of slow background activity, particularly 
the absolute power of the theta frequency band, in the EEG is markedly 
increased by CLO treatment and this finding correlates positively with clinical 
improvement in patients with SCH. CLO affected the production of ROS by 
blood MO with reduction or minimal increase of the ROS production being 
associated with clinical improvement, whereas marked increase of the ROS 
production did not. Also a positive correlation between theta absolute power 
increase in the EEG and suppression of the production of ROS by blood MO was 
found. The correlations between different symptom clusters of SCH and the 
EEG rhythms were investigated; the absolute power of beta activity in the EEG 
seemed to correlate positively to overall psychopathology in patients with SCH 
showing inadequate response.  
 
The results suggest that the EEG background activity and investigation of the 
production of ROS by MO seem to be an adjunctive method to objectively 
assess and possibly predict the therapeutic effect of CLO in patients with chronic 




1.1. Schizophrenia  
1.1.1. General description and etiology 
 
SCH is discussed in most cases as if it were a single illness. The diagnostic 
entity includes, however, a group of heterogeneous disorders with different 
courses, etiologies and responses to treatment (Sadock & Sadock 2003), even 
though they present with somewhat similar symptoms. In many cases the illness 
impairs substantially a patient’s ability to form social relationships, to acquire 
skills needed for daily living and working, as well as to organise their time and 
activities. It may also reduce their drive and motivation, distort perception and 
cause disorganization of thinking and decline in cognitive function. The 
implications of the impact of SCH on the quality of life of the patients and their 
relatives are severe because of the relapsing course of the illness, emotional 
burden, social stigma and marked decline in daily functioning of the patients. 
There is also an increased mortality associated with SCH (Barbato1998). 
 
The etiology of SCH still remains obscure. Several hypotheses have been raised 
over the years. The significance of genetic factors has been shown in twin 
studies with probandwise concordance rates of 41-65% in monozygotic twins 
and heritability estimates of approximately 80-85%. (Cardno et al 1999, Cardno 
& Gottesman 2000). The research has shown that in addition to genetic factors 
the environmental factors play a substantial role (30-50%) in the etiology of 
SCH – problems with maternal bonding, early rearing in poverty, immigration 
status, stress, complications during pregnancy and during birth, and perinatal 
viral infections contribute to the increased risk of  SCH (Sadock et al 2000). 
Tienari et al (2003) showed an increased prevalence of SCH in adopted-away 
off-springs of mothers having SCH or SCH spectrum disorder. 
 
The neurodevelopmental hypothesis is supported by a growing body of data and 
according to this hypothesis the neuronal cell birth, differentiation, migration, 
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synaptogenesis, programmed cell death and neuronal circuitry formation have 
been altered leading to behavioural and cognitive dysfunction (Bunney & 
Bunney 1999, Eastwood et al 2003). 
 
A “two hit” model has been proposed to explain the onset of SCH in early 
adulthood. The first hit consists of an early (antenatal) disruption of neural 
development and the second hit is an environmental stress during childhood 
/adolescence (McCarley et al 1999, Schiffman et al 2002). The hitting factors are 
considered to affect the brain’s development and maturation ultimately leading 
to the development of SCH.  
 
There has been no single causative factor identified and the strongest evidence 
suggests SCH being an inherited disorder which is exacerbated by external 
stress. The broad dysfunction of the brain neural networks seems to be present in 




1.1.2. Prevalence of schizophrenia 
 
SCH is a mental illness affecting approximately 1% of the World’s population 
(Schultz & Andreasen 1999, Norquist & Narrow 2000) although a wide range 
(0.3 - 17 per 1000) of prevalence has been reported in different studies (Torrey 
1987) and (4-7 per 1000) according systematic review Saha et al (2005). Studies 
have suggested that SCH appears to be slightly more prevalent in Finland than in 
most other western developed countries (Torrey 1987, Lehtinen et al 1990, 
Hovatta et al 1997, Suvisaari 1999, Perälä et al 2007). In Finland the prevalence 
of 1.3% was shown in the Mini-Finland Health Survey (Lehtinen et al 1990). In 
the recent publication of Perälä et al. (2007) a prevalence of SCH of 0.87 % was 
shown but SCH, schizoaffective disorder and schizophreniform disorder showed  
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a combined prevalence of 1.26%. The yearly incidence was 0.1-0.4 per 1000 and 
the mean age of onset was 24 years (Sham et al 1994).  
 
 
1.1.3. History, diagnosis and symptom clusters 
 
Some forms of psychosis have been described since ancient times. Galen (131 - 
ca. 200 AD) used the term “insanity” which may have referred to SCH among 
other psychotic conditions. SCH as an illness was only clearly differentiated 
from other psychotic illnesses and conditions at the end of the nineteenth century 
by Emil Kraepelin. Kraepelin named the conditions characterised by early onset 
and the permanent deterioration of mental functioning as Dementia Praecox in 
1893 (Harms 1971). He emphasised the gradual deterioration and decline of 
intellect, the weakening of volition and the emotional dullness caused by the 
illness. Kraepelin (1919) described the characteristic symptoms of SCH, not 
considering any single symptom, as pathognomonic for SCH. Kraepelin (1919) 
wrote: “Dementia praecox consists of a series of states, the common charac-
teristic of which is a peculiar destruction of the internal connections of the 
psychic personality. The effects of this injury predominate in the emotional and 
volitional spheres of mental life.”  
 
The diagnosis “schizophrenia” was proposed by Eugen Bleuler in 1911 and has 
been in use since. He wrote that the “splitting” of the different psychic functions 
is one of the most important characteristics of the illness. The impairment of the 
volition and emotions as well as the disorganisation of thinking was emphasized 
as the main characteristic of this illness by both - Kraepelin and Bleuler. Bleuler 
(1911) believed, however, that the disease includes probably several illnesses.  
Bleuler (1911) described the fundamental symptoms of SCH being disordered 
association, inadequate and flat affect, ambivalence, and autism. Fundamental 
symptoms of the illness remain observable also between relapses.   
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Schneider (1959) considered delusional perception, auditory hallucinations, 
passivity of thought and passivity experiences as being the First Rank 
Symptoms, which have also been used as fairly reliable criteria for diagnosis in 
clinical work.  The persistent delusions and auditory hallucinations have been 
also considered as the most specific diagnostic criteria (Schneider 1959, 
Feighner 1972, Spitzer 1975, DSM-III-R 1987).  
 
Kay et al (1987) clustered symptoms to positive, negative, and general and this 
symptom classification has become widely accepted in scientific research as well 
as in clinical work. The different symptom clustering of disorganisation, reality 
distortion, and psychomotor poverty proposed by Liddle (1987) has also been 
widely used in scientific research. Depending on which symptom cluster is 
dominating in the clinical picture, it can give some indication of potential 
differences in the course of the illness (Ho et al 2004), to some extent predict the 
response to treatment and make the prognosis. Patients with predominantly 
positive symptoms generally respond better to pharmacotherapy than patients 
with predominantly negative symptoms and marked cognitive deficit (Andreasen 
et al 1990). According to Liddle's classification the reality distortion and the 
disorganisation symptom clusters respond to conventional antipsychotics whilst 
psychomotor poverty cluster generally has a limited response.  
 
Diagnosis of SCH as a single entity, even today, remains challenged. The 
diagnosis of SCH is descriptive and is based on the structurally described 
psychiatric symptoms forming a nosological entity. The first classification 
implementing clear-cut descriptive criteria for psychiatric diagnoses and 
introducing the concept of mental disorder was Diagnostic and Statistical 
Manual, Third Revision (DSM-III) published by APA in 1980. Schizophrenic 
disorder was used in DSM-III but in the description of the disorder the term 
illness was still used (DSM-III 1980). Descriptive criteria used in DSM-III and 
in the revised version DSM-III-R (1987) became widely used diagnostic tools in 
clinical practice and research work both within and outside of the USA. 
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Although the etiology of SCH is not yet known, the concept of schizophrenia as 
an illness is commonly used and is also used in this introduction along with the 
term disorder.  
 
To date there are still no specific biological trait markers to verify the diagnosis 
of SCH. The diagnostic concepts of SCH presented by different sources differ to 
some extent even today and there is no total consensus regarding the core 
symptoms of the illness among psychiatrists.  
 
 
1.1.4. Brain pathology in patients with schizophrenia  
 
SCH has been considered a functional brain illness. Patients with SCH lack 
gross brain pathology but the hypothesis of minor morphological changes had 
been suggested by E. Kraepelin as early as 1905 (Rajarethinam et al 2005). The 
findings are localised predominantly in the fronto-temporal cortical areas, 
thalamus and hippocampal formation (Staal et al 1998 and 2001, Ettinger et al 
2001, Gaser et al 2004, Sim et al 2006). The pattern of abnormalities is 
suggestive of a disturbance of connectivity within and between these regions, 
most likely originating during brain development (Harrison 1999). At the same 
time, however, other studies do not support the presence of morphological 
changes (Hazlett et al 1999, Bagary et al 2002). 
 
The neural network modulation involves mutual links between different neuro-
modulatory systems making the neural network as a whole sensitive to the 
changes even in one modulatory system. The balance of dopaminergic, 
serotonergic, glutamatergic, and gamma-aminobutyric acid (GABA)-ergic 
neuromodulatory systems are most probably all affected in patients with SCH 
(Byne et al 1999, Javitt et al 2000, Javitt et al 2005). The most investigated 
neuromodulator in patients with SCH is indisputably dopamine. Dopamine has 
been shown to regulate local network activity in animal experiments (Honkanen 
 15 
1999, Bandyopadhyay & Hablitz 2007) and in patients with SCH (Dolan et al 
1995).  
 
Both families of dopaminergic receptors (D1-like family (D1 and D5) and D2-
like family (D2, D3, D4)) are considered to be affected in patients with SCH 
(Seeman et al 1989). The dopaminergic activity seems to be overactive 
subcortically (Breier et al 1997, Abi-Dargham et al 2000, Kienast & Heinz 2006) 
but at the same time there is growing evidence of insufficient dopaminergic 
activity and compensatory upregulation of cortical D1 receptors in the frontal 
cortical areas (Weinberger et al 1988, Abi-Dargham & More 2002, Hirvonen et 
al 2006). The increased density of D2 receptors in patients with SCH was shown 
by Sedvall & Farde (1995). The loss of D3 mRNA expression from other 
dopamine receptors in the parietal and motor cortices of postmortem brains of 
patients with SCH was shown by Schmauss (1993) and a six-fold increase in the 
density of D4 receptors in patients with SCH was found by Seeman et al (1993). 
The reasons and consequences of these findings still remain subject of scientific 
speculation. The receptors’ regulatory function in the central nervous system is 
also difficult to explore due to their plasticity and mobility in and out of synaptic 
space (Triller & Choquet 2005).  
 
Changes in neuromodulation possibly lead to the impaired integration of brain 
functions which clinically manifests with disorganisation of thoughts, inadequate 
affect, cognitive defect, disturbed odd behaviour and poor social functioning in 
patients with SCH. As several mediatory systems have been affected in SCH it 
might speak in favour of antipsychotics, which affect simultaneously several 







1.1.5. Treatment of schizophrenia  
 
Along with diagnostic questions the treatment of SCH remains a significant 
clinical challenge. Substantial progress in the treatment of SCH has been 
achieved during the last five decades but the illness still remains incurable. The 
treatment of the illness lasts for years and often requires a multidisciplinary 
approach. The course of the illness involves fluctuations in the intensity of the 
clinical symptoms. The patient's insight is crucially important to ensure the 
patent's adherence to treatment. Unfortunately there are still 30% of patients 
who, despite all treatment efforts and even with good adherence, respond poorly 
to treatment and experience relapse within a year of treatment (Steingard et al 
1994). Although there is no cure for SCH available, the treatment of the illness 
markedly reduces the symptoms and improves the social functioning of patients 
(Breier et al 1987, Swartz et al 2007).  
 
The antipsychotic medication affecting dopamine receptors in the brain has been 
in clinical use since the 1950-s. The results of treatment with drugs having 
antagonistic properties on brain dopamine receptors have been commonly used 
and the most effective form of treatment to date. According to research in the 
acute phase of illness antipsychotics effectively reduce positive symptoms in 
roughly 70 percent of patients and maintenance therapy reduces the risk of 
relapse (Dixon et al 1995). 
 
About 70% of patients with schizophrenia achieved remission compared to 
~25% patients receiving placebo treatment (Sadock & Sadock 2005). Some 
response to pharmacological treatment of new cases of SCH was reported being 
as high as 87% (Robinson et al 1999). The illness tends to relapse in 96% of 
cases after discontinuation of antipsychotic medication during 2 years according 
to Gitlin et al (2001). In other studies about 20 % of patients with SCH fail to 
respond to antipsychotic therapy (Kerwin & Bolonna 1995) and at the same time 
only 13.7% of subjects met full recovery criteria for 2 years or longer in the 
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study of Robinson et al (2004). These results indicate that about two thirds of the 
patients probably respond to the antipsychotic treatment partially.  
 
The non-adherence with treatment can contribute to treatment resistance. The 
satisfactory compliance rate in new cases of SCH treated with conventional 
antipsychotics was only 54% (The Scottish Schizophrenia research group 1987), 
Gilmer et al (2004) showed full adherence in 41% of beneficiaries with SCH. In 
many cases, however, the reason for the different responses to treatment remains 
obscure and the response to treatment for each patient individually remains 
difficult to predict despite good adherence. Treatment with antipsychotics has 
often been criticised because of the neurological side effects and limited efficacy 
in some of the patients. Even though antipsychotic medication has a problematic 
side effect profile of neurological, metabolic, hormonal, and haematological side 
effects, the antipsychotics remain an important part of the treatment showing the 
most robust treatment effect on the intensity of symptoms and on the course of 
the illness. The search for more effective drugs with more benign side effect 
profiles remains a challenge for psychopharmacological research.  
 
 
1.1.6. Treatment resistant schizophrenia  
 
Treatment resistant SCH is defined as showing failed or very limited response to 
two antipsychotics, one of which is an atypical, administered in therapeutic dose 
and sufficient duration (Taylor et al 2005). From all patients suffering from SCH 
10% to 30% show little or no response to antipsychotic medications (American 
Psychiatric Association 2004) and thus can be considered to be classified as 
treatment resistant. Treatment resistance may be a feature of the illness from its 
onset or it can develop in due course (Sheitman et al 1998). Beside 
ineffectiveness of medication the treatment resistance also might be related to 
comorbidity, substance misuse, poor adherence with treatment, and suboptimal 
dosing of medication (American Psychiatric Association 2004). The treatment 
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and management of treatment resistant SCH involves high doses of 
antipsychotics, combination therapy, CLO treatment, CLO augmentation and 
cognitive behavioural psychotherapy combined with psychoeducation. CLO, 




1.2. Clozapine  
1.2.1. Clozapine as an atypical antipsychotic  
 
Along with conventional antipsychotics with high affinity for D2 blockade there 
are antipsychotics available with different pharmacological properties and side 
effect profiles. CLO was synthesized in Switzerland in 1958 and subsequently 
recognised as an antipsychotic in 1959 (Meyer & Simpson 1997, Hippius 1999). 
It was taken in to clinical practice in 1972 but following eight reported deaths 
from agranulocytosis in Finland in 1975 (Idänpään-Heikkilä 1977) it was 
withdrawn from the market but was later reintroduced to clinical practice with 
safety guidelines. Currently it is generally used as a second line antipsychotic 
treatment for treatment resistant SCH. 
 
CLO has been proven the most efficient antipsychotic to date, being effective in 
30 - 50% of treatment resistant cases (Lieberman et al 1994, Wahlbeck et al 
1999). The full mechanism of action of CLO remains obscure but alongside the 
effect on different dopamine receptors the widespread effects on multiple 
mediatory systems in the brain might have a therapeutic role. CLO also probably 
affects the psychoneuroimmunology and neurophysiology of the brain.  
 
CLO has been considered as an atypical antipsychotic because it generally does 
not cause extrapyramidal side effects. The underlying reason is probably a 
limited binding to dopaminergic D2 receptors and it might also be related to 
CLO’s wide spectrum of action on many neuromediatory systems – 
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dopaminergic (Lahti et al 1993), histaminergic, glutamatergic (Malhotra et al 
1997), GABA-ergic (Drew et al 1990, Wassef et al 2003), noradrenergic 
(McMillen & Shore 1978, Gross et Schümann 1980), serotonergic (Audinot et al 
2001, Hagino et al 2002), and cholinergic (Parada et al 1997, Raedler et al 2003) 
systems. 
 
The effect of CLO on the dopaminergic system is also different from potent D2 
blocking drugs as CLO has higher affinity to D4 receptors (Lahti et al 1993, 
Sanyal & Van Tol 1997, Seeman et al 1997). CLO’s clinically active metabolite 
N-desmethyl-clozapine has been investigated recently and there have been 
intriguing reports about broad activity of this compound on cholinergic M1 
receptors and glutamate NMDA receptors (Sur et al 2003, Li et al 2005). N-
desmethyl-clozapine possibly also acts as a partial agonist of dopaminergic D2 
and D3 receptors similarly to the novel antipsychotic aripiprazole (Burstein et al 
2005).  
 
CLO still remains as a model for the newer atypical antipsychotics. Efficacy of 
CLO in treatment resistant patients has been shown in various studies. CLO has 
been shown to have an effect on suicidal behaviour (Meltzer and Okayli 1995) 
and almost all symptom clusters of SCH. Kane et al (1988) showed higher 
efficacy of CLO compared to conventional antipsychotics. Kuoppasalmi et al 
(1993) showed improvement in positive and negative symptoms after three to six 
months of CLO treatment in two third of patients with treatment resistant SCH.  
Improvement in positive symptoms by 1 month, in negative symptoms with 
improvement in social functioning by 3 months was shown in an open 
prospective trial by Jalenques et al (1992). The full clinical effect of CLO might 
in some cases appear only after 6 months of treatment (Meltzer et al 1990).  
According to Lieberman et al (1994) 50% of the patients with treatment resistant 
SCH and 76% of the treatment intolerant patients responded to 12 months trial 
of CLO treatment. Significant cognitive improvement, as measured by Wechsler  
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Adult Intelligence Scale-Revised (WAIS-R), was observed after a year of 
treatment with CLO in patients with treatment resistant SCH (Fujii et al 1997). 
 
 
1.2.2. Side effects of clozapine 
 
CLO is considered to be the first atypical antipsychotic as it does not generally 
cause neurological extrapyramidal side effects. At the same time the 
complication of metabolic side effects, epileptic seizures, leucocytopenia and 
potentially fatal agranulocytosis are related to CLO treatment.  
Weight gain has been shown to be more prevalent with CLO treatment (Bustillo 
et al 1996). Increased risk of metabolic syndrome with a prevalence of 54% 
compared to 21% in the general population in the US has also been demonstra-
ted (Lamberti et al 2006). Henderson et al (2000) showed that the patients 
treated with CLO experience significant weight gain, lipid abnormalities and 
appeared to have an increased risk of developing diabetes.  
 
Risk of epileptic fits was 1 - 4.4% and is dose-related (Devinsky et al 1991). 
However the incidence of epileptic fits was reported being as high as 9.4% by 
Liukkonen et al (1992) and 20% by Welch et al (1994). 
 
The risk of agranulocytosis and the substantial risk of death due to 
agranulocytosis only became evident in 1975 (Idänpään-Heikkila 1977). CLO 
has an inhibitory effect on the production of the blood granulocytes (Atkin et al 
1996). Haematological problems related to CLO treatment have been reported in 
3,6% of patients treated with CLO (Wahlbeck et al 1999) and the cumulative 
incidence of agranulocytosis after one year of CLO treatment was 0,8% (Alvir et 
al 1993). The reasons behind the development of agranulocytosis are not 
completely elucidated. Interesting results have been published recently by 
Bergemann et al (2007) who showed clozapine concentrations in the leukocytes 
of the patients who developed leukocytopenia eight times higher than those who 
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did not develop leukocytopenia. The elevated proapoptotic gene expression 
along with the ROS production in the neutrophils of the patients with CLO-
induced agranulocytosis is reported by Fehsel et al (2005). The direct toxicity of 
CLO is not certain at therapeutic concentrations but CLO undergoes 
bioactivation to a toxic, chemically reactive nitrenium ion (Maggs et al 1995, 
Pirmohamed et al 1995) and Williams et al (2000) showed that the neutrophil 
apoptosis was induced at therapeutic concentrations of CLO when it was 
bioactivated to a nitrenium ion. 
 
The haematological side effects remain the most concerning factors limiting the 
use of CLO in clinical practice. There are strict limitations and regulations 
applied to the use of CLO in clinical practice. In most countries a system for 
obligatory white cell count monitoring is established for the haematological risk 
management. 
 
Emergence of metabolic side effects seems to coincide with achieving the 
desired clinical effects. Meltzer et al (2003) reported the increase in weight 




1.3.1. General description and association with schizophrenia 
 
Psychoneuroimmunology deals with two basic processes: influence of mental 
activity on regulation of immunological processes and influence of autoimmuno-
logical reactions on neural activity and brain function (Solomon 1987, Ader 
2003). The CNS has influence over immunological function as well as regulation 
of hormonal production. Direct autonomic neural regulation has an effect on the 
immunological reactivity. There is a predominate sympathetic (mediated by 
catecholamines) input to all components of the immune system – e.g. thymus 
gland, spleen, lymph nodes, and bone marrow. Activation of the sympathetic 
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nervous system primarily inhibits the activity of cells associated with the innate 
immune system, while it either enhances or inhibits the activity of cells 
associated with the adaptive immune system. (Nance and Sanders 2007). 
 
There is evidence supporting the hypothesis of association between 
inflammatory process and SCH, at least in some patients (Leonard 2005). 
Leonard (2005) also emphasised that the genetic link (chromosome locus 6p22) 
between human lymphocyte antigen system and SCH as well as the 
epidemiologic finding of negative correlation between rheumatoid arthritis and 
SCH also indicates the possible involvement of immune component in SCH.  
 
Modern immunological methods have shown the innate as well as adaptive 
immune system to be involved in immune dysfunction in SCH. The increased 
number of MO/macrophages and activation of interleukine (IL)-6 indicate the 
activation of the innate system (Nikkilä et al 1999, Muller et al 1999). The 
elevated IL-6 serum levels have been found associated with duration of illness 
(Ganguli et al 1994) and the resistance to drug treatment (Lin et al 1998) in 
patients with SCH. There is evidence that the cellular arm (T-helper-1) of the 
adaptive immune system is reduced while the humoral arm (T-helper-2) is 
increased (Leonard 2005). The serum T-helper-2 shift, indicating relative 
activation of humoral type immune activity seems also to be specific for SCH 
(Muller et al 1999, Chiang 2005). According to existing data the effective 
treatment with antipsychotic drugs seems to restore the imbalance between these 
systems (Leonard 2005). 
 
The controversial results of different studies investigating the contribution of 
cytokines (IL-2) in SCH were analysed by Hinze-Selch & Pollmacher (2001). 
They concluded that despite different methodologies and study designs the 
medication and cigarette smoking are likely to play a role in the immune system 
changes in patients with SCH.  
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Despite the controversial research results and complicated interactions between 
immunological mechanisms there is currently little doubt about the involvement 
of immunological mechanisms in SCH. 
 
 
1.3.2. Free radicals and reactive oxygen species 
 
Free radicals are highly reactive chemical species or molecules (Cadet 1988). By 
definition a free radical is any atom or molecule possessing a free unpaired 
electron in the outermost shell and is capable of independent existence (Karlsson 
1997). This unpaired electron makes the free radical unstable and highly 
reactive. Free radical is “seeking” another balanced molecule from which to steal 
electrons. 90% of free radicals are produced in the mitochondria (Sidiropoulos 
2005). 
 
Free radicals involving oxygen can be called as reactive oxygen species (ROS). 
Most free radicals are ROS. The ROS family includes hydrogen peroxide 
(H2O2), superoxide (O2), hydroxyl (OH), peroxyl (ROO), alkoxy (RO), nitric 
oxide (NO), and peroxynitrite (ONOO). Limited amount of ROS are generated 
by normal cellular functions like arachidonic acid metabolism, mitochondrial 
respiratory chain, phagocytosis, ovulation and fertilisation. During pathological 
conditions the production of ROS multiplies several times and in excess they can 
damage lipids, proteins and DNA (Young et al 2007), increase lipid peroxidation 
(Phillips et al 1993) and alter anti-oxidant enzymes (Abdalla et al 1986). The 
toxicity and reactivity varies between different ROS. ROS may attack and 
damage the cell membrane or other structures that compose the cell by stealing 
electrons from the lipid membranes of a cell, which is known as lipid 
peroxidation (Helwig 2000). Additionally to cell membranes ROS can also 
damage or fragment DNA and modify proteins. These effects may ultimately 
lead to cell death.  
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ROS are mainly synthesized by immune cells and in the CNS by brain 
macrophages – microglia. Release of ROS has also been reported during the 
recovery phases from many pathological conditions in the brain (Fisher et al 
1988, Halliwell et al 1989, Fischer et al 2001, Halliwell 2006). It has been 
shown that NO is generated also by glial cells (Halliwell et al 1985). It has also 
been speculated that particularly NO is implicated in some neurodegenerative 
illnesses in CNS. 
 
 
1.3.3. Reactive oxygen species and schizophrenia 
 
There is some evidence indicating the role of ROS in the pathogenesis of SCH 
(Reddy & Yao 1996, Mahadik et al 2001). Sirota et al 2003 reported a positive 
correlation of ROS (superoxide) production by neutrophils with negative 
symptoms of SCH. Increased serum levels of NO were recently reported in 
patients with chronic SCH by Yilmaz et al (2007). 
 
The catecholamines (adrenaline, noradrenaline, dopamine) might be related to 
ROS generation in CNS, they can spontaneously break down or be metabolised 
by monoamine oxidase to ROS (Singh et al 2004). The increase of dopaminergic 
activity in SCH might lead to excessive breakdown of dopamine forming ROS 
and toxic quinolines. On the other hand dopamine has powerful antioxidant 
properties by several separate mechanisms – activation of the synthesis of 
antioxidative proteins, direct ROS scavenging and possibly acting via dismuting 
complexes (Smythies 2000). Smythies (1999) also showed that activation of D2 
receptors induces the synthesis of antioxidant enzymes. He also proposed that 
the function of neuroprotective catecholamine-iron complexes or neurotoxic 
catecholamineo-quinoline complexes may be deffective in SCH. Elevated 
sodium dismuthase activity has also been reported in patients with SCH, which 
is possibly an adaptive response to ROS overload as sodium dismuthase is a 
ROS scavenger (Abdalla et al 1986). Increased serum levels of sodium 
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dismuthase and thiobarbituric acid reactive substances (a measure of lipid 
peroxidation) have also been reported in patients with SCH (Gama et al 2006). 
 
Cigarette smoking is common among patients with SCH and it has been shown 
to aggravate the ROS production (Gustafsson et al 2000). On the other hand 
Zhang et al (2007) reported decreased oxidative stress and lipid peroxida-
tion in patients with SCH who smoked tobacco.  
 
Is seems that there is an increase in the level of free radical activity as well as 
antioxidants in the serum and possibly CNS of patients with SCH. 
 
 
1.3.4. Reactive oxygen species and antipsychotic medication 
 
There is contradicting data about the effect of antipsychotics on ROS production. 
The conventional antipsychotics have been shown in in vitro studies to produce 
an eight-fold increase in ROS production, whilst CLO and sulpiride did not 
induce a significant increase (Sagara 1998). Haloperidol increased production of 
ROS by mitochondria and antioxidants reduced cell death induced by 
haloperidol (Post et al 1998, Sagara 1998). In the same time serum levels of the 
tiobarbituric acid reactive substances (index of lipid peroxidation and oxidative 
stress) were significantly higher in CLO treated SCH patients than haloperidol 
treated SCH patients (Gama et al 2006). Bastianetto et al (2006) reported that 
CLO showed a neuroprotective effect but through a ROS independent and 
caspase dependent mechanism in hippocampal cells.  
 
Regarding other atypical antipsychotics the recent results of Kato et al (2007) 
indicate that risperidone significantly inhibited the production of nitric oxide and 
proinflammatory cytokines by activated microglia. Hou et al (2006) reported that 




It seems to be the case that all antipsychotics, atypicals and CLO affect immuno-
logical mechanisms and apoptotic systems in the neurons as well as peripheral 
blood cells. It is, however, unclear to what extent this influence is related 
directly to antipsychotic effect and what relates to the neuropathology of SCH. 
 
 
1.4. Electroencephalography  
1.4.1. General description  
 
Electroencephalography (EEG) is a non-invasive neurophysiological investi-
gation method. EEG is a registration of brain electrical activity recorded from 
the surface of the scalp. The electrodes are attached to the surface of the scalp to 
pick up the electrical activity which is recorded by the EEG machine. Electrode 
placement is determined by measuring the head and marking the scalp. The 10-
20 International System of Electrode Placement (Jasper 1958) (Appendix 2) is 
used by the great majority of EEG labs throughout the world (Hughes 1994). 
The numbers 10 and 20 refer to percentages of the distances between electrodes. 
There are 19 electrodes attached to the scalp and two to the earlobes as reference 
electrodes. The electrodes are called prefrontal, frontal, central, temporal, 
parietal and occipital electrodes and they record the electrical activity from the 
same cortical regions respectively.  
 
Voltage differences between different parts of the scalp are measured in the EEG 
but not electrical currents (Fish 1999). The frequency of the spontaneous 
electrical activity has a range from less than 1 Hz up to 80Hz. The main 
frequencies investigated are in the range of 1 – 20 (25) Hz and are arbitrarily 
divided in to four ranges: Delta (1 – 3.5 Hz), Theta (4 – 7,5 Hz), Alpha (8 – 13 
Hz) and Beta (13 – 25 Hz). The frequency band 25 - 35 Hz has been called Beta 
II and the frequency band above 35 Hz the Gamma frequency (Boutros & Braff 
1999). The change in electrical activity can be noticed with a good temporal 
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resolution (1ms) and moderate spatial resolution (10-15 mm) (Volkow et al. 
1996).  
 
The EEG consists of the inhibitory and excitatory postsynaptic potentials 
generated mainly in the cortex of the brain (Fish 1999). The EEG is a result of 
summation of the electrical activity of the clusters of brain cells. The weak 
electromagnetic fields caused by depolarisation of every single brain cell will be 
summarised due to simultaneous rhythmic firing of the cells.  The electrical 
impulses produced by the brain have a voltage of only tens of microvolts and 
thus the signal has to be amplified for the EEG registration. The brain electrical 
activity has to be filtered from various artefacts such as electrical activity caused 
by muscles, the heart or from possible external sources (Hughes 1999).  
 
The brain has a complex cortical surface. The EEG registers the electrical 
activity from the closest cortical area and predominantly from the gyri which 
generate a radial electromagnetic field (Barkley & Baumgartner 2003). The 
pyramidal cells in the IV cortical layer are the main source of EEG activity. The 
rhythmic activity probably originates from the interaction of the brain cortex and 
thalamus (Fish 1999). In addition to neurons there are also glial cells involved in 
brain electrical activity, amplifying the electrical fields and affecting the spatial 
distribution of the fields (Boutros & Braff 1999).  
 
The EEG has been used from the time of its discovery to diagnose epilepsy and 
to identify focal as well as generalised organic brain pathology (Hughes & John 
1999, Smith 2005). The EEG can be analysed visually by an experienced neuro-
physiologist or it can be digitalised and quantified by computer which enables 
more detailed analysis of the EEG. The development of digital technology and 
more sophisticated mathematical analysis methods of EEG, such as quantitative 
EEG (QEEG), has opened new possibilities for the use of the EEG in diagnostic 
work (Hughes & John 1999). 
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1.4.2. Quantitative electroencephalography  
 
QEEG is based on the quantitative analysis of the EEG signal. The 
“background” EEG signal from 21 attached electrodes at a standardised eyes-
closed resting position is recorded, digitalized and stored. From the stored data a 
sample of 1 to 3 minutes of artefact-free EEG is visually edited and analysed.  
The powers of frequency bands of delta, theta, alpha, and beta rhythms are 
calculated using the Fast Fourier Transformation (FFT) mathematical algorithm. 
The averaged power spectrum values of the frequency bands are produced for 
each electrode across the entire sample, known as the power spectrum. Results 
can be represented as absolute power (total µV2) or relative power (percentage of 
total power), there is also used coherence (phase synchronization of two 
channels), or symmetry (the ratio of power between a symmetrical pair of 
electrodes) (Hughes & John 1999). 
 
The analysis of the QEEG power spectrum gives a detailed picture of the brain 
background electrical activity. According to Hughes and John (1999) studies 
have shown QEEG to be both a specific and sensitive method for investigating 
psychiatric disorders even though the method does not have currently clinical 
applications. On the other hand Nuwer (1997) expressed his concerns regarding 
overoptimistic application of QEEG in clinical practice but still acknowledged 
the progress which has been made in the scientific understanding of cerebral 
dysfunction in many disorders including SCH. QEEG is currently not approved 
for diagnostic purposes of psychiatric disorders (Coburn et al 2006), but could 
have corroborative value in making clinical pharmaco-therapeutical decisions.  
 
QEEG could be useful in clinical practice for assessment of the efficiency of 
antipsychotic medication. Change in the absolute power spectrum of the theta 
frequency band in the QEEG has been shown to correlate with the antipsychotic 
effect of medication (Chobor et Volavka 1992, Omori et al 1995, Kikuchi et al 
2005). 
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1.4.3. EEG background activity  
 
Spontaneous rhythmic electrical activity is observed in the brain which is 
dependent on mental activity, emotional state, level of arousal and age. It is also 
influenced by psychotropic substances. The EEG varies substantially between 
different individuals but it remains, however, a relatively stable characteristic for 
one individual (Salinsky et al 1991, Williams et al 2005).  
EEG background electrical brain activity is regulated by anatomically complex  
homeostatic systems. Cortical processes are modulated by the brainstem and 
thalamus using all the major neurotransmitters (McCormic1992, Lopez da Silva 
1996). Different rhythms are believed to reflect different neurophysiological 
states. The cortical activity also most likely reciprocally influences subcortical 
structures to make possible fast switching from one functional state of the brain 
to another necessary for adequate responding to external stimuli.  
 
The pacemaker function probably originates mainly from the brainstem and the 
rhythm is further modulated in the thalamus. The beta rhythm (13-20 Hz) is 
believed to reflect thalamocortical and corticocortical interneural transactions 
related to specific information processing. The alpha rhythm (8-13 Hz) is the 
dominating frequency in the EEG of an alert adult person at rest. Modulating 
neurons throughout the thalamus normally oscillate synchronously in the alpha 
rhythm which is globally distributed across the cortex. Gamma-aminobutyric 
acid (GABA) release by the nucleus reticularis diminishes sensory throughput by 
thalamic neurons to the cortex which is observed as a slowing in the dominant 
alpha rhythm into the theta range (4-7,5 Hz). Delta activity (1-3,5 Hz) probably 
originates from oscillator neurons in deep cortical layers and in the thalamus. 
These neurons are normally inhibited by the ascending reticular activating 
system in the midbrain (Hughes & John 1999). Slower rhythms are related 
mainly to deep sleep stages, states of unconsciousness, diffuse brain pathology 
as well as treatment with antipsychotics. Faster rhythms are related to anxiety, 
task solving and treatment with anxiolytics.  
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Changes in background activity related to mental disorders are generally subtle 




1.4.4. The EEG and Schizophrenia  
 
The first recorded EEG of a patient with psychotic disorder was probably in 
Cambridge in 1936 (Lemere 1936). It was followed by reports of Berger (1937) 
who invented the EEG in the first place. Davis (1940, 1942) referred to 
“disorganisation” and “choppy activity” (probably consisting of a low voltage 
beta activity) in the EEG of psychotic patients. She also classified patients with 
SCH in to 3 groups: Group I -Essentially normal. Group II: Dysrhythmic type, 
which is indistinguishable from EEG's of individuals known to have convulsive 
disorders. Group III: "Choppy" type, which suggests the possibility of a 
pathological condition in the brain (Davis 1940).  
 
Early reports of Jasper (1939) and later Goldstein (1965) reported low amplitude 
and prominent slow wave activity in EEG records of patients with SCH. 
Numerous qualitative studies have indicated abnormal EEG findings in range 
20% to 60% of schizophrenic patients (Ellingson 1954, Small 1984, 1993, 
Sponheim 1994). According Hughes and John (1999) 68% of psychiatric 
patients’ EEGs, provide evidence of a dysfunction of the brain. In the same time 
Centorrino et al (2002) indicated the presence of EEG abnormalities in less than 
20% of psychiatric inpatients.  
 
The quantification of the EEG and the power spectral analysis enabled more 
detailed analysis of the EEG. Itil et al (1972) reported increased beta, theta and 
delta activity in patients with SCH. Whether EEG findings are state or trait 
related features in patients with SCH has been a matter of dispute for decades 
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(Sengoku & Takagi 1998). Stassen et al (1999) found that the EEG 
abnormalities associated with SCH manifested differently in co-twins 
concordant for SCH, and suggested that it reflects the non-genetic, pathological 
developments of genetically identical brains. Winterer et al (2001) supported this 
with his findings and proposed that power spectrum EEG abnormalities may be 
state-dependent in patents with SCH. Equally there are features in the EEG that 
might reflect genetic vulnerability and should be considered as a trait related 
characteristics. These parameters are coherence (Winterer et al 2001), reduced 
amplitudes of auditory evoked potentials (Weisbrod et al 1999, Ahveninen et al 
2006) and probably reduced pre-pulse inhibition of the startle response (Hamm 
et al 2001). The current data suggests that the state dependant and the trait 
related changes probably both exist in the EEG of patients with SCH. 
 
Different symptom clusters have correlated with EEG changes. Negative 
symptoms have correlated with an increase of delta (Guenther et al 1988, Gattaz 
et al 1992) and beta band (Williamson et al 1989) activities. Karson et al (1988) 
and Sponheim et al (2000) showed that increased low-frequency power and 
diminished alpha-band power was associated with negative symptoms, enlarged 
ventricles and cortical atrophy. Positive symptoms were correlated to theta and 
delta activities in a magneto-encephalographic study (Fehr et al 2001).  
Harris et al. (1999, 2001) reported correlations between QEEG frequency band 
powers, Liddle's three factors (Liddle 1987) of psychomotor poverty, 
disorganisation, and reality distortion and the negative and positive subscales of 
the Positive and Negative Syndrome Rating Scale (PANSS) (Kay et al 1987). 
Liddle's factors showed positive correlations with delta, alpha, and beta bands. 
The PANSS negative subscale correlated positively with delta power.  
 
Topographically the most robust EEG findings have been reported predomi-
nantly over the anterior, temporal and central regions in patients with SCH. The 
correlations of symptom clusters with dysfunction of particular cortical areas is 
mainly localised to the fronto-temporal area (Itil et al 1972, Barta et al 1990, 
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Kawasaki et al 1996). Treatment resistant patients with SCH exhibited greater 
overall absolute theta power, slower mean alpha frequency and elevated absolute 
delta and total power in the anterior regions (Knott et al 2001). Positive and 
negative SCH were found to differ only in the delta and theta bands over frontal 
regions (Begic et al 2000).  
Psychiatric symptoms are most likely a consequence of dysfunction of multiple 
cortical areas and sub-cortical brain structures in patients with SCH.  
 
 
1.4.5. The EEG and antipsychotics  
 
The effects of medication on the EEG background activity were reported soon 
after antipsychotics were discovered (Jorgensen & Wulff 1958, Itil 1968, 1972). 
Antipsychotics have been shown to increase alpha power (Galderisi 1994, Saletu 
1994, Schellenberg 1994) and reduce beta power in both short and long term 
administration (Herrmann 1986, Niedermeyer 1987, Hughes & John 1999) 
reversing some findings reported in patients with schizophrenia. Abnormal EEG 
changes have been described in hospital patients (with various diagnoses) on 
antipsychotic treatment. Abnormalities occurred in 19.1% of patients treated and 
in 13.3% of patients not treated with antipsychotics. Abnormality rates among 
patients taking conventional antipsyhotics ranged from 36.4% with 
trifluoperazine to 7.3% with haloperidol, with intermediate rates in other 
antipsychotics of high or low potency (13%–14% with chlorpromazine, 
perphenazine, or thioridazine) and in subjects not treated with antipsychotics 
(13,3%) (Centorrino et al 2002).  
 
Max Fink (2002) emphasised that the term "abnormality" comes from 
neurological literature that uses visual impressionistic methods to assess EEG 
records. But psychoactive drugs induce only subtle changes that are not always 
detected by visual analysis. The quantitative digital computer processing is an 
adequate method for detecting the effect of drugs on EEG (Fink 1985). 
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Therefore he considered the description of the EEG changes associated with 
psychoactive drugs as “abnormal” or “normal” as misleading. 
 
The EEG changes caused by antipsychotics appear to relate to their clinical 
effect. Antipsychotic medication has been shown to attenuate beta frequency 
power particularly in patients responding to medication (Itil et al 1972, Guenther 
et al 1988). Change in the absolute power of the theta frequency band in the 
QEEG has been shown to correlate with the antipsychotic effect of medication 
(Chobor et Volavka 1992, Kikuchi et al 2005). Antipsychotics having different 
properties also seem to have different effects on the EEG. The modern atypical 
agents, increasingly used in clinical practice, have variable effect on the EEG. 
The risk of EEG abnormality was highest with CLO (47.1%), followed by 
olanzapine (38.5%) and risperidone (28.0%), with a few quetiapine treated 
patients having no abnormalities (Centorrino et al 2002).  
The predictive value of the EEG on clinical effect has been the subject of 
numerous studies.  
 
Pretreatment beta power and asymmetries in delta and theta were associated with 
overall clinical improvement (Czobor & Volavka 1993). Galderisi et al 1994 
showed that the patients showing the same response in QEEG as healthy subjects 
(i.e. increased theta and alpha1 activity) six hours after being given a test dose of 
haloperidol or clopenthixol had more favourable clinical response to treatment.  
Pharmaco-EEG has the potential for clinical applications. Several QEEG studies 
have shown consistent findings on early predictors of treatment response to first 
generation antipsychotics but the findings have so far not had clinical impact 
(Mucci et al 2006). 
 
The pathological EEG findings in patients with SCH are affected by anti-
psychotic treatment. These findings may indicate further deterioration of brain 
function or reflect reparative or compensatory mechanisms and this remains a 
subject for future research. 
 34 
1.4.6. The EEG and clozapine 
 
It seems evident that the effect of CLO on the EEG is greater than that of other 
antipsychotics (Small et al 1987, Centorrino 2002). CLO induces an increase of 
slow frequencies in the background EEG activity in patients suffering from SCH 
(Tiihonen et al 1991, Guenther et al 1993, Risby 1993, Knott et al 2001) as well 
as in healthy volunteers. This effect was seen even after single dose of CLO 
administration (Saletu et al 1987, Galderisi et al 1996), and is greater than that 
seen in the newer atypical antipsychotics (Schuld et al 2000, Centorrino et al 
2002). The degree of pathological findings in the QEEG has been suggested to 
correlate positively with the degree of clinical response to CLO treatment (Risby 
et al 1995), and with CLO plasma levels (Haring et al 1994, Freudenreich et al 
1997). Stevens (1995) rise a hypothesis of the important role of subcortical 
structures in development of psychosis and presented an argument for evaluating 
the EEG slow waves caused by CLO as evidence of its therapeutic activity. The 
EEG changes after CLO, especially when instrumentally quantified, 
demonstrated the predictive value of the EEG (Roubicek & Major 1977). CLO is 
also known to give rise to epileptiform disturbances as well as disturbances in 
the background activity on EEG (Tiihonen et al 1991, Guenther et al 1993, 
Risby et al 1993, Treves & Neufeld 1996, Alper et al 2007). The CLO effect on 
brain neurophysiology is marked probably due to the affinity of the drug to 
multiple mediatory systems. The high antipsychotic efficacy seems to be related 
to widespread effect of CLO on various neural networks. 
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2. AIMS OF THE STUDY 
 
In this work, the effect of CLO on the EEG and ROS production in patients with 
SCH was studied. The aim of the study was to clarify the effect of CLO on EEG 
power spectrum and ROS production by MO and explore the relationship of 
these effects with clinical response. We also tried to clarify whether the EEG 
changes or ROS production by MO would help to identify the patients who were 
most likely to respond to treatment with CLO.  
 
The specific aims of the studies were: 
I – II  To investigate prospectively the association between effect of CLO on 
ROS production by MO and clinical outcome in patients responding 
inadequately to conventional antipsychotics and the temporal correlation of these 
changes. 
 
III  To study the QEEG changes characteristic to CLO treated patients compared 
to patients treated with other antipsychotics and healthy volunteers. QEEG 
absolute power spectrums between groups of patients receiving various anti-
psychotics with patients receiving CLO medication and healthy controls were 
compared. 
 
IV  To study changes in ROS production by MO and the association with the 
QEEG absolute power spectrum in patients responding inadequately to 
conventional antipsychotics and being treated with CLO. 
 
V  To investigate prospectively the association between clinical outcome and 
QEEG power changes in patients responding inadequately to conventional 
antipsychotics and being treated with CLO.  
 
VI  To study the association between QEEG main frequency absolute powers 
and different symptom clusters of psychiatric symptoms in patients showing mi-
nimal or no clinical improvement to treatment with conventional antipsychotics. 
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3. SUBJECTS AND METHODS 
3.1. Patients and study design 
3.1.1 Patients  
The main characteristics of subjects and patients being investigated in studies I – 
VI have been presented in Appendix I. 
 
 
3.1.1.1 Patients in the studies I, II, and IV 
 
Eight inpatients from Tammiharju Mental Hospital (mean age 31,4 years) with 
chronic SCH ( according to DSM-III-R ) responding inadequately to treatment 
with conventional antipsychotics were studied. Patients did not have organic 
brain damage, neurological disorders, allergic states, acute infections, 
hyperthermia (>37oC), history of alcohol or drug-abuse, previous history of CLO 
treatment or any medication beyond the patients continuous psychiatric 
medication used within the last 2 weeks (3 months for steroids and antibiotics). 
The patients had previously received conventional antipsychotics (mean dose 
386 mg chlorpromazine equivalents. Before baseline testing and QEEG 
recording there was at least a 36-hour wash-out period. Treatment with CLO 
started with a dose of 50 mg/day. The dose was thereafter increased stepwise by 
50mg every third day. The final treatment dose was chosen according to the 
clinical need and the decision of the psychiatrist responsible for the treatment of 
the patients. Benzodiazepines and chloral hydrate in minimal effective doses as 
sleeping agents were allowed as if needed medication.  
 
 
3.1.1.2 Patients in study III 
 
A group of 21 patients with chronic SCH receiving various antipsychotics (non-
CLO group), a group of 21 patients with chronic SCH receiving CLO treatment 
(CLO-treated group) and a group of 29 healthy volunteers were investigated.  
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The mean age in the CLO-treated group was 37.6 years, the average duration of 
illness was 15.7 years, duration of treatment with antipsychotics 15.5 years, and 
the mean dosage of CLO was 514 mg/day.  
The mean age in the non-CLO group was 39 years, average duration of illness 
was 13.7 years, mean duration of treatment with antipsychotics was 13.2 years. 
Patients were medicated with one to three antipsychotic drugs simultaneously, 
the average dose being 405 mg chlorpromazine equivalents. Patients with any 
organic brain lesion, history of heavy alcohol or drug abuse, concomitant 
neurologic illness, organic psychosis or other psychotic disorders were excluded. 
The control group consisted of 29 subjects (mean age 35 years), none of whom 
had psychotropic medication. They were healthy volunteers from the hospital 
staff without any neurological or psychiatric disease. 
 
 
3.1.1.3 Patients in studies V and VI 
 
The sample, who consisted of sixteen inpatients (mean age 32.6 years) suffering 
from SCH considered as having insufficient clinical response to conventional 
antipsychotic treatment and evidencing a relapse of the illness with PANSS 
mean total score 103 (range: 67–137), were investigated prospectively. The 
mean duration of illness was 10.4 years and they were previously treated with 
conventional antipsychotics corresponding to 386 mg chlorpromazine equiva-
lents for 9.4 years on average. None of them had received CLO prior to the 
study. Before baseline investigation there was at least a 24 (up to 72)-hour wash-
out period from previous conventional antipsychotic treatment. Treatment with 
CLO was started after the baseline visit and the same protocol was followed as 
in the studies I, II and IV with a dose of 50 mg/day. During the study the use of 
other psychoactive drugs, except benzodiazepines and chloral hydrate as 
hypnotics, was not allowed. The benzodiazepines were not allowed in the 
evenings preceding the QEEG registrations. Patients did not have neurological 
disorders or a history of alcohol or drug abuse.  
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3.1.2 Study Design 
3.1.2.1 Design of  studies I, II, and IV 
 
The studies were designed as a 10 weeks prospective setting. The correlation 
between the increase of theta power in the EEG and ROS production by MO was 
prospectively investigated in eight patients with SCH and receiving CLO. 
Inpatients from Tammiharju hospital who fulfilled the inclusion criteria and gave 
informed consent were investigated. There was no control group. Patients were 
started on CLO treatment and were investigated on three occasions; before 
treatment with CLO, three and ten weeks after the initiation of the CLO. 
Assessments consisted of QEEG registration and Positive and Negative 
Syndrome Rating Scale (PANSS) (Kay 1987) conducted by a psychiatrist. In the 
EEG the midline frontal electrode (Fz) was chosen to investigate on the basis of 
our earlier research.  Blood sampling for the investigation of ROS production 
and CLO blood levels were done on the same day. The results of the assessments 




3.1.2.2 Design of study III 
 
This was a cross sectional study where two groups of patients were compared 
with age matched healthy controls. The patients receiving CLO in various doses 
were included in one group, the patients with other antipsychotic medication and 
not having CLO, were included in another group. The QEEG investigations and 






3.1.2.3 Design of studies V and VI 
 
The study V was done in an open label prospective setting. Sixteen patients who 
were started on CLO treatment during the study recruitment period in 
Tammiharju Hospital, fulfilled the inclusion criteria and had given consent were 
investigated. There was no control group. The patients were investigated on five 
occasions; before treatment with CLO, after one, three, ten and sixteen weeks 
after the initiation of the CLO. Assessments consisting of QEEG registration and 
PANSS were conducted by a psychiatrist. Blood samples were drawn in the 
morning (before the first CLO dose of the day) for the investigation of CLO 
plasma levels. The results of EEG power spectrum analysis were correlated to 
PANSS results. The results of the assessments were calculated and analysed only 
after completion of all assessments and data collection. PANSS ratings of 
patients were performed blind to the QEEG results. 
 
The same patients were investigated in the study VI using data from visit 1 
before treatment with CLO was started. The results of EEG power spectrum 
analysis were correlated to PANSS subscale results and also to Liddle's three 
symptom clusters calculated from PANSS items. The antipsychotics were 
suspended for12-36 hours before clinical assessment and QEEG. 
 
 
3.2 Blood sampling, isolation of mononuclear leukocytes and reactive 
oxygen species assessments 
3.2.1 Studies I, II and IV 
 
Blood samples were taken between 07.45-08.00 a.m. during every visit 
(smokers’ samples were taken immediately after the first cigarette of the day) 
before the first CLO dose of the day. Total leukocyte counting was performed 
with a Counter Coulter (Counter Electronics, UK) from anticoagulated blood 
within 1 hour of blood sampling. At the same time blood smears were made for 
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differential count. Samples were calculated blindly and thereafter the results 
were analysed. 
 
Polymorphonuclear leukocytes and mononuclear leukocytes were isolated using 
10 ml of heparinised venous blood, layered on 7 ml Ficoll-Paque (Pharmacia, 
Sweden) within one hour of blood sampling and centrifuged at 450 g for 20 min 
at 20o C. The band in the interface between the plasma and the Ficoll layer, 
containing lymphocytes and MO, was aspirated and washed once in phosphate 
buffered saline. The leukocyte count was determined with the Counter Coulter, 
and the cell suspension was diluted to 5 x 106 mononuclear cells/ml. 
Cytocentrifuge preparations of the cell suspension were prepared immediately, 
dried in room air and stained with May-Grünwald-Giemsa for determination of 
the MO proportion. The mononuclear cell suspension (50 μl) was added to a 
solution containing 5.6 mM luminol (Bio-Orbit, Finland). One half of the 
samples were stimulated with 0.1 μg/ml phorbol myristate acetate. The light 
emission caused by the production of ROS, mainly hypochlorite (DeChatelet 
1982), was recorded for 30 min at 2-min intervals with a Bio-Orbit 1251 
luminometer (Bio-Orbit, Finland). All measurements were performed in 
duplicate. The results are expressed as the areas under the light emission curves 
per 100,000 cells. The MO results were corrected for the actual MO count on the 
basis of the differential count obtained from the cytocentrifuge preparations. 
At baseline, before treatment with CLO, ROS production was also studied by 
adding CLO dissolved in water 5 mg/l after incubation at 37 o C for 1 hour. 
 
 
3.3 Quantitative EEG Recordings 
3.3.1 Quantitative EEG recording and data selection in studies III, IV, V, and VI  
 
QEEG recordings were performed in the neurophysiology laboratory in 
Tammiharju Hospital. Cadwell Spectrum P32 equipment was used. EEGs of the 
patients were recorded digitally as part of clinical work. Healthy controls were 
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investigated in the same laboratory using similar settings. QEEG recordings 
were performed between 9 a.m. and 1 p.m. During recording the subjects were 
awake with their eyes closed. The alpha frequency amplitude in the posterior 
parts of the brain was visually monitored and regular verbal contact with the 
subject was taken to control the vigilance. The EEGs were analysed afterwards.  
The standard 10–20 electrode placement system with 21 electrodes on the scalp 
and one on both earlobes was used in recording. The sampling rate was 200 Hz, 
with a low-pass limit of 70 Hz, and a time constant of 0.3 second. The digital 
recordings 10-20 minutes in duration were saved on optical disks. 
 
The topographical quantitative calculations were made using the Cadwell 
Spectrum P32 Neurometrics program (Cadwell Laboratories, Kennewick, WA), 
with the ear electrodes as a reference. The digital EEG recordings were screened 
visually and 48 2.5-second artefact-free epochs were selected from the typical 
background for subsequent analysis. As a result of the Fast Fourier 
Transformation, the averaged power spectral values of the delta (1.5-3.0 Hz), 
theta (3.0-7.5 Hz), alpha (7.5-12.5 Hz), and beta (12.5-20.0 Hz) bands were 
produced for each of the 21 scalp electrodes separately. 
 
 
3.3.2 Quantitative EEG calculations 
3.3.2.1. Quantitative EEG calculations in study III 
 
The absolute power values of all four main frequency bands at each electrode 
location were compared respectively and the correlations statistically tested 
between the CLO group, the non-CLO group, and the healthy subjects. Due to 
skewed distributions, the nonparametric Kruskal-Wallis test and Spearman's 





3.3.2.2. Quantitative EEG calculations in study IV 
 
QEEG was analyzed at the central frontal electrode (Fz) only. Theta frequency 
absolute power at this electrode was chosen based on our earlier research results 
(Study III), which show that CLO-caused changes are similar in all electrodes of 
frontal, central, and parietal regions and most specifically at Fz.  
 
 
3.3.2.3. Quantitative EEG calculations in studies V and VI 
 
The theta frequency band (3,5-7Hz) in the fronto-central scalp area was chosen 
to be observed on the basis of the results of Study III, where we showed a widely 
distributed marked increase in the theta band with prominence in the fronto-
central midline scalp area in the schizophrenic patients treated with CLO. For a 
greater accuracy the absolute theta powers of electrodes on fronto-central left 
(FCleft) (Fp1, F3, C3), midline (FCz) (FpZ, FZ, CZ), and right (FCright) (Fp2, 
F4, C4) scalp areas were averaged. The averaged absolute powers for FCleft, 
FCz and FCright were calculated for each patient separately and afterwards 
correlations with clinical parameters were calculated. 
 
 
3.4 Clinical assessments 
3.4.1 Positive and Negative Syndrome Scale 
 
Positive and Negative Syndrome Scale (PANSS) is a 30-item rating instrument 
including 3 subscales: for positive symptoms (7 items), for negative symptoms 
(7 items), and for general symptoms (16 items). The scale is developed by Kay 
et al 1987 for evaluating the presence/absence and severity of psychopathology 
of the SCH. The PANSS was originally developed using the BPRS and the 
Psycho-pathology Rating Scale. All 30 items are rated on a 7-point scale (from 
1=absent, to 7=extreme).  
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3.4.2. Liddle’s Factors 
 
Liddle's proposed three factors (Liddle 1987) called reality distortion, 
disorganisation and psychomotor poverty. Liddle made a finer distinction 
between the two relatively independent dimensions within the positive symptom 
cluster (hallucinations and delusions) and the “disorganised” symptoms of 
disorganised speech, disorganised behaviour, and inappropriate affect (Arndt et 
al 1995). 
Factors were derived from 14 PANSS items describing characteristic symptoms 
of each factor (reality distortion – P1, P3, P6; disorganisation – P2, G5, G9, 
G11; psychomotor poverty – N1, N2, N3, N4, N6, N7, G7). The items were 
chosen in collaboration with professor P.Liddle. 
 
 
3.5 Statistical analysis 
3.5.1. General 
 
The study results are given in mean + SD, or mean + range. Differences were 
usually considered statistically significant for a priory hypothesis when the P 
value was less than 0.05, when multiple calculations were used, the P value was 
considered significant if less than 0.001. The SYSTAT Version 5 (1992) 
software was used for statistical calculations. The statistical methods used in the 
studies are presented as follows. 
 
 
3.5.2. Statistics in studies I and II 
 
For non-parametric data the Wilcoxon’s non-parametric test and Spearman’s 
correlation coefficient were used in the calculations in Study I and Study II. In 
Study II multivariate analysis of General Linear Modelling (Dillon and 
Goldstein 1984) was used in addition. 
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3.5.3. Statistics in study III 
 
The nonparametric Kruskal–Wallis test and Spearman’s ranked correlation 
coefficient were used for comparing the mean absolute power values between 




3.5.4. Statistics in study IV 
 
Mean values and Standard Deviations were calculated, Spearman’s correlations 
were used to correlate the means of changes in theta power value in the Fz 
electrode and the ROS production by MO. Multivariate analysis MGLH 
(Multivariate General Linear Hypothesis) and General Linear Modeling, with 
stepwise exclusion of dependent variables, was used.  
 
 
3.5.5. Statistics in study V 
 
Wilcoxon’s signed ranks test was used to check the differences between the 
baseline values and subsequent PANSS scores, and theta powers. Spearman’s 
correlation coefficient was used for calculation of correlations.  
 
 
3.5.6. Statistics in study VI 
 
Spearman's correlations were used for calculating correlations between QEEG 
powers and clinical parameters. An alpha level was set on 0.05. Multivariate 
analysis MGLH and General Linear Modelling were used to test the influence of 




All the recruited patients were started on CLO for clinical reasons. The protocols 
of all these studies comply with the laws and ethical standards of Finland and the 
Fifth Revision of the Declaration of Helsinki. The study protocol was authorised 
by the Ethics Committee of Tammiharju Hospital in Tammisaari. After complete 
description of the study, a written informed consent was obtained. Patients were 
recruited in whom a change of medication was considered appropriate on a 
clinical basis. The course of treatment was decided by the clinician responsible 
for treatment. Patients were able to withdraw their consent at any time. 
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5. RESULTS 
5.1. Effect of clozapine on the production of reactive oxygen species by 
monocytes. Studies I and II 
 
The ROS production was studied prospectively in eight patients for ten weeks. 
Although ROS production did not show significant longitudinal trends during 
the trial, the changes in ROS production by non-stimulated (MOn) and phorbol 
myristate acetate (PMA)-stimulated MO (MOs) at week 3 (values at base-line 
minus those at week 3) correlated positively with the changes on the total 
(p=0·035 and p=0·009, respectively) and negative ( p=0·045 and  p=0·027, 
respectively)  Positive and Negative Syndrome Scale (PANSS) subscales. 
Production of ROM by MOs at week 10 correlated positively with PANSS 
positive subscale ( p=0·049). A decrease or relatively small increase in the ROM 
production by MOn and MOs was associated with more favourable clinical 
outcome than a clear-cut increase in their ROS production. The serum 
concentrations of CLO at week 3 also correlated positively with the changes in 
ROS production by MOs at week 3 (p=0·047) and at week 10 ( p<0·001). 
 
The ROS production by MOn decreased after incubation in vitro with CLO at 
weeks 0 (baseline) and 3, with a similar trend seen also at week 10 of the trial. 
The ROS production decrease by MOn after CLO incubation in vitro at week 0 
correlated positively with subsequent improvement in clinical symptomatology 
(PANSS total scores and subscales) at weeks 3 and 10 with exemptions of 
positive subscale at week 3 and negative subscale at week 10. The most 









5.2. EEG findings in patients taking conventional antipsychotics, clozapine 
and healthy subjects. Study III 
 
The main difference between the CLO-treated group and the other groups was 
increased absolute theta power values. Statistical testing suggested significant 
differences (P < 0.001) in the mean delta and theta power values on the FC 
between the CLO-treated and the non-CLO group as well as healthy controls. 
There was observed a wider range of absolute theta power values in the CLO-
treated group compared with the healthy subjects and the non-CLO-treated 
group. There was no significant difference at any electrode in either the alpha 
power or the beta power distributions between the groups. There was no 
statistical difference in the delta, theta, alpha, or beta power values between the 
two hemispheres in any group. 
 
 
5.3. The correlation of EEG findings with production  of reactive oxygen 
species by monocytes. Study IV 
 
The changes in the ROS production and theta power values of the Fz -electrode 
showed a clear-cut negative correlation after 3 weeks of CLO treatment (p < 
0.005) for non-stimulated and (p < 0.001) stimulated MO. After 10 weeks of 
treatment there was no statistically significant correlation between these 
parameters.  
 
The reduction of ROS production by MO after incubation with CLO in vitro 
correlated positively with the increase in theta power after 3 weeks (r =0,738, 
p<0,05), but after 10 weeks no correlation was observed. 
 
The above correlations were examined further using multivariate stepwise 
analysis. The change in theta power of the Fz electrode was the dependent 
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variable and the change in ROS production, age, serum CLO level and duration 
of illness were independent variables. The increase of theta power in Fz was 
explained by the change in ROS production only: R2= 0,929, p<0,05 for non-
stimulated, and R2= 0,907, p<0,001 for stimulated MO.  
 
 
5.4. Theta power changes in patients receiving CLO treatment. Study V 
 
After three, ten, and eighteen weeks of CLO treatment a clear-cut increase in 
theta power was observed in all electrode groups similarly, emerging most 
prominently in the midline. The increased theta power remained virtually 
unchanged after ten weeks of treatment.  
 
After 3 weeks there were significant positive correlations between theta power 
increase in the midline and reduction in the PANSSP (p<0,05), and between 
theta power increase in all electrode groups and reduction in the PANSSN 
(p<0,01). After 10 weeks a significant correlation between theta power change in 
all electrode groups and changes in the PANSSG and PANSSP were observed 
(p<0,05). After 18 weeks some trend of inverse correlation between changes in 
the PANSSG and PANSSN and theta power change were observed, but not with 
regard to PANSSP. Mainly theta power change in FC left and right areas were 
found similar to midline.  
 
A trend of positive correlation between change in PANSS and serum CLO levels 








5.5. The correlation between different symptom clusters and the 
Quantitative EEG power spectrum. Study VI 
 
Sixteen patients receiving different antipsychotic treatment were investigated. 
The hypothesis was postulated according to earlier research data of Harris et al 
(1999). Significant positive correlations were found between beta and 
psychomotor poverty (p<0.05) supporting the a priori hypothesis. Trends to 
positive correlations (p<0.1) were observed between delta and PANSS negative 
subscale and Liddle’s psychomotor poverty. Alpha did not correlate with reality 
distortion and delta did not correlate with disorganisation. 
 
Post hoc analysis revealed positive correlations of the same magnitude between 
beta power and psychopathology generally over FC. Delta power showed 
positive correlation with PANSS negative subscale on the midline FC. MGLH 
testing for the influence of sex, age, and anxiolytic medication on the a priori 
hypothesized correlation between beta power and psychomotor poverty on FCz 
revealed that age as a factor strengthened the correlations, other variables were 




6.1. Methodological aspects  
 
This work can be considered as an attempt to clarify the mechanism of action of 
CLO and the ways forward in the development of biological markers for SCH 
and CLO treatment response. In the study it was found that CLO treated patients 
had marked slowing fronto-centro-parietally in the EEG which was associated 
with clinical improvement. Changes of ROS production by MO in patients 
treated with CLO seemed to predict the clinical improvement. The EEG findings 
were observed widely over the scalp indicating the involvement of multiple 
cortical areas in the brain related to neurophysiopathology of SCH. The results 
have been shown in patients suffering from chronic schizophrenia and 
experiencing relapse. Whether the results apply to SCH generally can not be 
answered on the basis of this study. It would also be fair to state that, following 
this study, the mechanism of action of CLO still remains obscure.  
 
The study has some strengths as hospital inpatients were used, the adherence 
with medication was supervised, plasma concentrations for the CLO were 
monitored, and substance misuse during the study was highly unlikely. There 
was no concomitant antipsychotic treatment allowed with CLO. The patients 
who had had CLO treatment at any time in the past were excluded from the 
studies. The study was designed in an open setting although the data was 
analysed only after completion of the study. 
 
The study has a number of limitations – a relatively small number of subjects, 
with only three patients not responding to CLO, a short wash-out period, no 
placebo, and no control group and due to the lack of control group the biological 
variation of ROS production by MO and EEG variation can not be taken into 
account. Other antipsychotic medication varied before initiation of CLO. A 
placebo response, especially at the beginning of CLO treatment, can not be ruled 
out as an explanation of the initial drug effect. 
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6.2 Effect of clozapine on reactive oxygen species production 
 
There is currently evidence that ROS may play an important role in the 
pathophysiology of SCH. The elevated levels of free radicals and distorted 
balance between oxidants and antioxidants have been reported in patients with 
SCH (Dakhale et al 2004, Gama et al 2006). The atypical antipsychotics seem to 
modify activity of free radicals in CNS (Dakhale et al 2004). According to 
Metodiewa & Koska (2000) there are a number of reports suggesting the 
involvement of free radicals in a variety of pathological events and multistage 
disorders including neurotoxicity and apoptotic death as well as implications of 
involvement in Alzheimer's disease, Parkinson's disease and SCH.  
In our study we found that CLO caused inhibition of production of ROS by 
blood MO in vitro predicted clinical improvement. We also found positive 
correlation between changes in ROS production by MO and clinical 
improvement. Our findings support the hypothesis of CLO having antipsychotic 
effect partly by modifying ROS production. 
 
As peripheral blood MO may serve as a model for brain macrophages – 
microglia, the changes in ROS production might happen also in the brain, 
modulating neural processes and thus have a role in the pathophysiology of 
SCH. The reasons behind the superior antipsychotic efficacy of CLO over 
conventional antipsychotics in treatment of SCH remain obscure, but 
involvement of many mechanisms including neuroimmunological ones is one 
possible explanation. In our sample the patients were experiencing acute relapse 
and one might speculate that the ROS driven active neurotoxic processes were 






6.3 EEG findings in patient with various antipsychotic medication, patients 
receiving clozapine and healthy subjects 
 
Marked slowing in EEG caused by CLO was observed in this study. The 
increased amount of theta and delta activity was widespread but was emphasized 
in the frontal, central and parietal areas in the patients treated with CLO. The 
effect was detected in patients who were treated with CLO only or with CLO 
and with other antpsychotic drugs simultaneously. Patients treated with various 
other conventional antipsychotics did not differ significantly from healthy 
controls. The observed slowing of EEG readings during CLO treatment seems to 
reflect similar widely distributed changes of brain electrical activity.  
 
Small et al. (1987) reported similar topographic EEG changes in theta amplitude 
during pure CLO treatment. The pharmachological mechanisms behind the 
slowing remain obscure, anticholinergic effect does not singularly account for 
this as patients taking various other antipsychotics with anticholinergic 
properties did not show EEG changes of the same magnitude. 
According to Small et al. (1987), chlorpromazine being a potent anticholinergic 
drug also slows EEG readings on the central and anterior scalp areas. In our 
work the slowing was not explained by chlorpromazine. Some patients had 
conventional antipsychotics in addition to CLO. Omitting of the eight patients 
who received CLO together with other antipsychotics, did not, however, affect 
the results.  
 
The EEG changes observed in the fronto-centro-parietal scalp area might 
indicate functional change in the cortical areas of these regions as well as the 
reflection of the change in the functional activity of the limbic system. N-
desmethylclozapine, the active metabolite of CLO potentially has partial 
agonistic properties similar to the partial D2 agonist aripiprazole (Burstein et al 
2005) and thus it might selectively activate mesocortical dopaminergic pathways 
and inhibit mesolimbic ones as has been suggested in aripiprazole. In the rat, 
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CLO is known to affect neurotransmission preferentially in the mesocortico-
limbic system, including the medial prefrontal cortex (Wang et al., 1994; 
Yamamoto et al., 1994). Morstyn et al. (1983) have reported both increased theta 
and delta on frontal areas, and increased beta on the left anterior temporal area in 
medicated patients with SCH compared with healthy control subjects. These 
differences are probably small compared with the remarkable slowing caused by 
CLO. In our study the healthy group and the group treated with other 
antipsychotics did not differ from each other except in delta power value at a 
single central occipital electrode (Oz).  
 
Our results suggest widely distributed, marked EEG changes caused by and 
specific for CLO. 
 
 
6.4 Reactive oxygen species production and EEG findings  
 
In this study we investigated the correlation between inhibited ROS production 
by MO and increase of theta activity in eight patients receiving CLO. The 
increase of theta power showed negative correlation with ROS production by 
MO after three weeks of CLO treatment. It is possible that the finding reflects a 
direct simultaneous effect of CLO on the theta power and ROS production by 
MO. However, in the multivariate analysis the change in theta activity was better 
explained by change in ROS production than by serum CLO concentration.  
 
One may speculate that EEG slowing is a result of the modulatory action of the 
activated microglia cells in CNS via production of ROS or cytokines or both. 
Microglia and activated microglia (brain macrophages) are able to produce ROS 
and the neurotoxic effect of activated microglia-produced ROS has been 
connected with diverse brain pathology including SCH (Banati et al 1993, 
Oken1995, Metodiewa 2000). MO may be used as a model for microglia, since 
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they share numerous functions, including production of ROS and cytokines 
(Langermans et al 1994, Chao et al 1995, Sacerdote at al 1995, Rock et al 2004).  
Cytokines have been reported to affect the production of biogenic amines in the 
CNS (Dunn et al 1995) and catecholamines (being biogenic amines) at the same 
time might regulate the cytokine response in CNS (Szelenyi & Vizi  2007). 
Biogenic amines have been shown to affect the EEG spectral power in the alert 
state as well as the EEG patterns during sleep (Crochet & Sakai 1999, Sebban et 
al 1999) in animal studies. In the present study this mechanism would provide an 
explanatory link between activation of microglia and slowing in the EEG.  
 
The superior efficacy of CLO can possibly be explained by the effect of the drug 
on the brain physiology involving various neuromodulatory, immunological, and 
possibly metabolic processes. These processes might have an impact on 
neuroplasticity which is reflected also in the brain electrical activity. It also 
supports the hypothesis of possible involvement of neuropsychoimmunological 
mechanisms in the therapeutic effect of CLO. 
 
 
6.5 Changes of theta power in patients receiving clozapine treatment  
 
The sixteen patients started on the CLO treatment were prospectively studied to 
test the hypothesis of correlation between theta increase and therapeutic 
response. The hypothesis was raised on the basis of clinical observations. Prior 
to the present study we supposed that the absolute theta power increase preceded 
the clinical response to CLO treatment. However, the increase in theta power 
was not observed prior to the clinical response. The CLO induced theta power 
increase in FC emerged prominently almost two weeks later than the initial 
clinical response was observed after a week of CLO treatment. The marked theta 
power increase was observed three weeks after CLO was initiated and it 
correlated with clinical response after three and ten weeks of treatment. The 
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theta power increase was only minimal in those patients who did not respond to 
CLO.  
 
Higher serum CLO concentrations seemed to be associated with better treatment 
responses in the beginning of the treatment, but not after ten and eighteen weeks. 
One reason for this may be that CLO, having been dosed according to clinical 
response, was overdosed in patients who responded poorly. While the 
correlations between treatment response and theta power increase were 
significant after three and ten weeks of treatment, there were no significant 
correlations between treatment response and serum CLO level. The change in 
theta frequency in the QEEG and particularly in the midline electrodes over the 
FC might be a more sensitive indicator for the evaluation of CLO treatment 
adequacy than the serum CLO level. 
 
The explanation might be that theta power increase possibly reflects the receptor 
occupancy by CLO in the brain and the effect of the drug on brain function and 
is a better indicator of treatment adequacy than the CLO serum level. The 
mechanism of CLO induced theta increase is not completely understood, but 
along with the anticholinergic effect (Adler et al 2002) of CLO the influence on 
the many modulatory systems in the brain might be involved. 
 
Our results indicated that midline EEG registration probably reflects reliably the 
clinically relevant changes in the EEG power spectrum related to SCH. 
 
 
6.6 The correlation between different symptom clusters and the EEG  
 
The correlation between symptom clusters and theta activity in patients 
evidencing relapse of SCH and responding inadequately to antipsychotic 
medication was investigated in this study. We postulated the a priori hypothesis 
according to the results of Harris et al (1999) where PANSSN score correlates 
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positively with delta power, Liddle's psychomotor poverty with delta and beta 
powers, disorganisation with delta power and reality distortion with alpha power. 
The finding of our study only partly supported the hypothesis - in the FCz 
significant correlation was found between beta absolute power and psychomotor 
poverty and the delta power showed trends towards positive correlation with 
PANSSN and Liddle's psychomotor poverty. We did not, however, observe 
correlation between delta and disorganisation and between alpha and reality 
distortion factors.  
 
In supplementary analysis the correlations of the same magnitude, despite being 
post hoc findings, were seen between beta power and all clinical parameters over 
FC. The correlation between symptom clusters and absolute beta power 
indicated that the overall symptomatology correlates with absolute beta power. 
The correlation of beta power with a wide spectrum of symptoms was also 
proposed by Itil et al (1972). This finding supports the link between EEG 
background activity and severity of symptoms of SCH. 
 
The psychiatric illness affects several mental functions simultaneously and, most 
probably affects the functioning of the whole neural network. The EEG 
background activity reflects the function of the neural network with good time 
resolution. Abundant beta activity in the EEG was probably the first report of 
EEG changes in patients with SCH. Davis (1940) reported “choppy activity” 
which probably referred to low voltage beta frequency. Earlier the increased beta 
activity has been suggested to be related to hyperarousal maintained by the brain 
stem (Sponheim et al 2000) and auditory hallucinations (Gaser et al 2004, 






In patients with SCH the resting cortical electric activity is probably altered 
which is reflected in the EEG of the FC. Psychiatric symptoms are most likely a 
consequence of dysfunction of multiple cortical areas and subcortical brain 
structures in patients with SCH, which is also supported by findings of Gaser et 





The main results and conclusions are: 
 
I   Patients treated with CLO showed widespread marked slowing in the QEEG 
compared to patients treated with other antipsychotics as well as healthy 
controls.  
 
II   After three and ten weeks of CLO treatment an association between ROS 
production by MO (in vivo) and clinical improvement was found. CLO inhibited 
ROS production by MOn (in vitro) at baseline which seem to predict the clinical 
response. 
 
III   Theta power increase in QEEG was associated with clinical improvement in 
CLO treated patients experiencing relapse of SCH and responding inadequately 
to treatment with conventional antipsychotics. 
 
IV   Changes in EEG activity in patients with SCH treated with CLO are 
diffusely located in the fronto-centro-parietal scalp area and are most robustly 
observed in the theta frequency band and culminate on the midline. 
 
V   Theta power increase in QEEG associated with CLO treatment was reflected 
by changes in ROS production by MO. 
 
VI   Beta power value is associated with negative symptoms and seems to 
correlate with overall psychopathology in patients evidencing relapse and 
responding inadequately to treatment with conventional antipsychotics. 
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8. FUTURE CONSIDERATIONS  
 
In the future larger samples using narrower diagnostic criteria and applying 
long-term prospective research settings with control groups should be 
considered. The QEEG, used for investigating the brain background activity, 
seems to be a relevant and valid method for SCH research. It is worthwhile 
investigating the role of the ROS production by MO as a possible important 
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11.1. Appendix 1 
 








Mean age, in 
years 
Sex  













II, and IV 
Patients,  
chronic 
SCH 8 31,4 (24 - 41) 1 / 7 9 (2 - 22) 8,9 (1 - 22) 516 (300 - 900) 
Study III 
Healthy 













treatment, 21 37,6 (19 - 60) 13 / 8 15,7 (3 - 27) 15,5 (3 - 27) 





SCH 16 32,6 (22 - 43) 7 / 9 10,4 (2 - 26) 9,4 (1 - 23) 386 (0 - 900) 
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11.2 Appendix 2 
 
Graph shows the location of electrodes according to The International 10-20 
Electrode Placement System. Grey area indicates the fronto-central scalp area, 
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